OncoMatch/Clinical Trials/NCT07170644
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Is NCT07170644 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nirogacestat oral tablet for desmoid tumor.
Treatment: Nirogacestat oral tablet — This study is being conducted to characterize the efficacy and safety of nirogacestat in Japanese adults with progressing desmoid tumors/aggressive fibromatosis.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: gamma secretase inhibitor
Participant previously received or is currently receiving gamma secretase inhibitors or anti-Notch antibody therapy
Cannot have received: anti-Notch antibody therapy
Participant previously received or is currently receiving gamma secretase inhibitors or anti-Notch antibody therapy
Cannot have received: tyrosine kinase inhibitor
Participant is currently using any treatment for DT/AF including tyrosine kinase inhibitors (TKIs) or any investigational treatment 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment
Cannot have received: investigational treatment
Participant is currently using any treatment for DT/AF including tyrosine kinase inhibitors (TKIs) or any investigational treatment 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment
Lab requirements
Blood counts
adequate organ and bone marrow function
Liver function
no severe hepatic impairment
Participant has adequate organ and bone marrow function; Participant has known severe hepatic impairment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify